Capecitabine: A Review of Its Pharmacology and Therapeutic Efficacy in the Management of Advanced Breast Cancer

摘要: Capecitabine is an orally administered prodrug of fluorouracil which indicated in the US and Europe, combination with docetaxel, for treatment patients metastatic breast cancer failing anthracycline therapy, as monotherapy resistant to paclitaxel therapy (US) or intensive chemotherapy (Europe). also approved use colorectal cancer. metabolically activated preferentially at tumour site, shows antineoplastic activity synergy other cytotoxic agents including cyclophosphamide docetaxel animal models. Bioavailability after oral administration close 100%. In pretreated advanced cancer, capecitabine effective agents. Combination 1,250 mg/m(2) twice daily 2 weeks every 3-week cycle plus intravenous 75 on day one each was superior 100 cycle. significantly reduced risks disease progression death by 35% (p = 0.0001) 23% 25% incidence). While gastrointestinal events hand-and-foot syndrome occurred more often than a regimen cyclophosphamide, methotrexate (CMF), neutropenic fever, arthralgia, pyrexia myalgia were common paclitaxel, nausea, stomatitis, alopecia asthenia CMF. The incidence adverse effects hospitalisation similar receiving those monotherapy. conclusion, capecitabine, convenient addition polychemotherapeutic patients, has potential component first-line regimens. Combined resulted rates treatment-related seen phase II data are promising. occur tolerability profile comparatively favourable (notably, neutropenia alopecia).